Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Matthew Gehl is a partner in the firm’s New York office and a member of the Corporate Practice Group.  He practices corporate and securities law, with a focus on the representation of underwriters and issuers in equity and debt capital markets transactions.  He also advises clients on disclosure and other securities laws issues, corporate governance matters and other general corporate matters.

  • Representing the underwriters in the pending initial public offering of a biopharmaceutical company focused on monoclonal antibody therapeutics targeting cancer stem cells.
  • Represented the underwriters in offerings by a leading manufacturer and marketer of consumer and professional products of an aggregate of $900 million of investment-grade notes.
  • Represented the underwriters in the $54 million initial public offering and subsequent $79 million follow-on offering of a life sciences company in the human genome sequencing and analysis space.
  • Represented the underwriters in a $76 million registered equity follow-on offering by a developer and marketer of aesthetic laser treatment systems and a selling stockholder.
  • Represented the underwriters in numerous offerings of an aggregate of approximately $2.4 billion of registered equity and debt securities of real estate investment trusts in the health care and senior living industries.
  • Represented the underwriters in multiple public offerings of investment-grade notes and common stock of a large financial services firm totaling approximately $2.8 billion.
  • Represented a manufacturer of specialty metal products in a $130 million Rule 144A/Reg S offering of senior secured notes.
  • Represented the underwriters in the $72 million follow-on public offering of common stock of a provider of inpatient and outpatient behavioral health care services.
  • Represented a leading developer, manufacturer, and marketer of life science tools and systems for genetic analysis in an $800 million Rule 144A offering of convertible notes.
  • Represented the underwriters in the $105 million accelerated book-build/wall-cross public offering of American Depositary Shares of a clinical-stage biopharmaceutical company focused on developing improved treatments for cardiovascular disease.